What is the appropriate dosing regimen for valproic acid (VPA) in adults and children, including starting dose, titration schedule, maximum dose, and special considerations such as hepatic impairment and enzyme‑inducing drug interactions?

Valproic Acid Dosing

Start valproic acid at 10-15 mg/kg/day in divided doses for both adults and children ≥10 years, increase by 5-10 mg/kg/week to achieve seizure control, with usual effective doses below 60 mg/kg/day and therapeutic plasma levels of 50-100 mcg/mL. 1

Starting Dose and Titration

Complex Partial Seizures (Adults and Children ≥10 years)

Monotherapy:

• Initial dose: 10-15 mg/kg/day
• Increase by 5-10 mg/kg/week until optimal response
• Target: Usually <60 mg/kg/day achieves control
• Therapeutic range: 50-100 mcg/mL 1

Adjunctive Therapy:

• Add valproic acid at 10-15 mg/kg/day to existing regimen
• Same titration schedule: increase by 5-10 mg/kg/week
• When converting to monotherapy, reduce concomitant antiepileptic drugs by approximately 25% every 2 weeks 1

Absence Seizures

• Initial: 15 mg/kg/day
• Increase weekly by 5-10 mg/kg/day
• Maximum: 60 mg/kg/day 1

Divided Dosing Requirements

If total daily dose exceeds 250 mg, give in divided doses 1. This is critical because standard delayed-release formulations cannot maintain therapeutic levels with once-daily dosing at higher doses—simulations show once-daily dosing of ≥2000 mg produces mean peak concentrations ≥125 mcg/mL, risking toxicity 2.

Maximum Dose Considerations

No recommendation for safety above 60 mg/kg/day can be made 1. However, pediatric patients often require higher maintenance doses (>60 mg/kg/day) to maintain concentrations >50 mg/L, particularly those on polytherapy 3. The probability of thrombocytopenia increases significantly at trough levels above 110 mcg/mL in females and 135 mcg/mL in males 1.

Special Populations

Pediatric Patients

Children have 50% higher clearance (mL/min/kg) than adults and require larger weight-based maintenance doses 1. This is particularly important because:

• CYP2C9-mediated oxidation becomes the principal metabolic route in children (versus a minor pathway in adults) 4
• Children on enzyme-inducing drugs need substantially higher doses 3
• Age >2 years significantly reduces hepatotoxicity risk, but children <2 years face considerably increased fatal hepatotoxicity risk 1

Hepatic Impairment

Valproic acid is contraindicated in patients with hepatic disease or significant hepatic dysfunction 1. This is non-negotiable given the risk of fatal hepatotoxicity, particularly in the first 6 months of treatment. Monitor serum liver tests prior to therapy and at frequent intervals 1.

Elderly Patients

Start at reduced doses in elderly patients and monitor closely for somnolence 1. A study in elderly patients with dementia revealed drug-related somnolence requiring dose reduction or discontinuation 1. Consider dosage reductions in patients with excessive somnolence.

Enzyme-Inducing Drug Interactions

Enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, phenobarbital, primidone) markedly accelerate valproate metabolism—dosage may need to be doubled to maintain therapeutic levels 5. This effect is particularly pronounced in children 5.

For induced patients:

• IV maintenance: Two-fold higher doses required 6
• Oral maintenance: Two-fold higher doses required 6
• Monitor valproate levels closely when enzyme inducers are introduced or withdrawn 1

Conversely, valproate inhibits metabolism of other drugs:

• Phenobarbital dosage must often be reduced after adding valproate 5
• Monitor levels of concomitant phenytoin, carbamazepine, lamotrigine, ethosuximide 1

IV Loading and Maintenance (Acute Settings)

For status epilepticus, IV valproate 30 mg/kg at infusion rates up to 6 mg/kg/min is effective and well-tolerated 7. Following IV loading:

Uninduced patients:

• Children: 7.5 mg/kg q6h IV starting 6 hours after loading 6
• Adults: 3.5 mg/kg q6h IV starting 6 hours after loading 6

Transitioning to oral:

• Delayed-release formulations: Begin within 2 hours of loading dose due to delayed absorption 6
• Extended-release formulations: Can be initiated concurrently with IV loading 6

Formulation-Specific Considerations

Extended-release divalproex is appropriate for once-daily dosing across a wide dose range, but standard delayed-release divalproex is NOT appropriate for once-daily dosing at high doses 2. Once-daily delayed-release divalproex at ≥2000 mg produces excessive peak-trough fluctuation (4.4-6.2-fold greater than extended-release) and risks toxicity 2.

Critical Monitoring Parameters

• Baseline and frequent liver function tests, especially in first 6 months 1
• Platelet counts and coagulation tests at higher levels 1
• Ammonia levels if unexplained lethargy, vomiting, or mental status changes occur 1
• Therapeutic drug monitoring when target response not achieved or when enzyme inducers/inhibitors are added 1

Absolute Contraindications

• Hepatic disease or significant dysfunction 1
• Known mitochondrial disorders (POLG mutations) 1
• Suspected POLG-related disorder in children <2 years 1
• Urea cycle disorders 1
• Pregnancy (unless other medications unacceptable) and women of childbearing potential (unless essential) due to teratogenicity and decreased IQ in offspring 1